| 1.47 0.05 (3.52%) | 12-04 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 1.74 |
1-year : | 2.03 |
| Resists | First : | 1.49 |
Second : | 1.74 |
| Pivot price | 1.35 |
|||
| Supports | First : | 1.31 |
Second : | 1.21 |
| MAs | MA(5) : | 1.41 |
MA(20) : | 1.33 |
| MA(100) : | 1.65  |
MA(250) : | 0 | |
| MACD | MACD : | 0 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 80.2 |
D(3) : | 75.8 |
| RSI | RSI(14): 59.1 |
|||
| 52-week | High : | 3.2 | Low : | 1 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ BCDA ] has closed below upper band by 11.5%. Bollinger Bands are 40.6% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 21 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 1.49 - 1.5 | 1.5 - 1.51 |
| Low: | 1.38 - 1.39 | 1.39 - 1.4 |
| Close: | 1.46 - 1.47 | 1.47 - 1.48 |
BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases. Its lead therapeutic candidate is the CardiAMP Cell Therapy System for the treatment of heart failure and chronic myocardial ischemia; and allogeneic cell therapy for cardiac and pulmonary disease. The company is also developing allogeneic cells therapeutic platform, an investigational culture expanded bone marrow derived mesenchymal cell therapy, which is in Phase I/II trial for the treatment of ischemic systolic heart failure. In addition, it offers the Helix biotherapeutic delivery system that delivers therapeutics into the heart muscle with a penetrating helical needle from within the heart; and Morph deflectable guides and sheaths. The company is based in Sunnyvale, California.
Wed, 03 Dec 2025
BioCardia (NASDAQ: BCDA) elects Marvin Slosman to board, honors Dr. Krasno - Stock Titan
Mon, 01 Dec 2025
BioCardia (NASDAQ: BCDA) to Discuss Heart Failure Cell Therapy at CSI Focus D-HF - Stock Titan
Mon, 24 Nov 2025
BioCardia Strengthens Leadership Team with The Addition of Farhan Shahab as Vice President of Quality - GlobeNewswire
Fri, 14 Nov 2025
BioCardia, Inc. (NASDAQ:BCDA) Q3 2025 Earnings Call Transcript - Insider Monkey
Wed, 12 Nov 2025
Earnings call transcript: Biocardia Q3 2025 focuses on heart therapy progress - Investing.com
Tue, 11 Nov 2025
Earnings Outlook For BioCardia - Benzinga
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 11 (M) |
| Shares Float | 7 (M) |
| Held by Insiders | 26.5 (%) |
| Held by Institutions | 4 (%) |
| Shares Short | 175 (K) |
| Shares Short P.Month | 306 (K) |
| EPS | -1.42 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.25 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -86.5 % |
| Return on Equity (ttm) | -317.5 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | -0.5 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -0.81 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -8 (M) |
| Levered Free Cash Flow | -4 (M) |
| PE Ratio | -1.04 |
| PEG Ratio | 0 |
| Price to Book value | 5.88 |
| Price to Sales | 0 |
| Price to Cash Flow | -2.08 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|